Zacks Research Reduces Earnings Estimates for Avanos Medical

Avanos Medical, Inc. (NYSE:AVNS - Free Report) - Equities researchers at Zacks Research reduced their Q2 2025 EPS estimates for shares of Avanos Medical in a research report issued on Tuesday, May 27th. Zacks Research analyst R. Department now expects that the company will post earnings of $0.18 per share for the quarter, down from their previous forecast of $0.26. The consensus estimate for Avanos Medical's current full-year earnings is $1.32 per share. Zacks Research also issued estimates for Avanos Medical's Q3 2025 earnings at $0.19 EPS, Q4 2025 earnings at $0.29 EPS, Q2 2026 earnings at $0.24 EPS, Q3 2026 earnings at $0.30 EPS, Q4 2026 earnings at $0.38 EPS, FY2026 earnings at $1.16 EPS and FY2027 earnings at $1.34 EPS.

Avanos Medical (NYSE:AVNS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.07. Avanos Medical had a return on equity of 4.70% and a net margin of 2.30%. The firm had revenue of $167.50 million for the quarter, compared to the consensus estimate of $161.75 million. During the same quarter last year, the business posted $0.22 EPS. The company's revenue for the quarter was up .8% on a year-over-year basis.

Separately, Wall Street Zen raised Avanos Medical from a "hold" rating to a "buy" rating in a research note on Wednesday, March 19th.

Avanos Medical Stock Down 0.5%

Shares of AVNS traded down $0.06 during midday trading on Thursday, hitting $12.58. The stock had a trading volume of 415,935 shares, compared to its average volume of 364,351. The company has a 50 day simple moving average of $12.81 and a two-hundred day simple moving average of $15.25. Avanos Medical has a twelve month low of $11.84 and a twelve month high of $25.36. The firm has a market cap of $581.75 million, a price-to-earnings ratio of 37.00 and a beta of 1.13. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.22 and a quick ratio of 1.46.

Insider Transactions at Avanos Medical

In other news, SVP Kerr Holbrook sold 7,000 shares of the company's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $15.25, for a total value of $106,750.00. Following the sale, the senior vice president now directly owns 82,047 shares of the company's stock, valued at approximately $1,251,216.75. This represents a 7.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 2.64% of the company's stock.

Institutional Investors Weigh In On Avanos Medical

A number of institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Avanos Medical by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 5,339,778 shares of the company's stock valued at $85,009,000 after purchasing an additional 19,476 shares during the period. T. Rowe Price Investment Management Inc. raised its holdings in shares of Avanos Medical by 24.8% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 3,757,576 shares of the company's stock valued at $53,847,000 after purchasing an additional 746,264 shares during the period. Armistice Capital LLC bought a new stake in shares of Avanos Medical in the 1st quarter valued at about $28,660,000. Brown Advisory Inc. raised its holdings in shares of Avanos Medical by 1.4% in the 1st quarter. Brown Advisory Inc. now owns 1,931,163 shares of the company's stock valued at $27,674,000 after purchasing an additional 26,069 shares during the period. Finally, William Blair Investment Management LLC raised its holdings in shares of Avanos Medical by 2.1% in the 4th quarter. William Blair Investment Management LLC now owns 1,406,210 shares of the company's stock valued at $22,387,000 after purchasing an additional 28,608 shares during the period. 95.17% of the stock is owned by institutional investors.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.